SDBB_Lab_OneGlasses.jpg

Precision Blood™

The Future of Blood Transfusion

San Diego Blood Bank is bringing greater precision to transfusion medicine through next-generation sequencing.

 

Precision Blood is practical personalized medicine, using next-generation sequencing (NGS) to provide more precise matching of blood type. This medical technology allows physicians to proactively and cost-effectively prevent potential negative responses to transfusion from the patient’s immune system, potentially impacting the lives of millions of patients each year.

With over 30 blood groups and more than 300 antigens (proteins and carbohydrates found on the surface of red blood cells*, there are hundreds of ways in which your blood might be unique and millions of possible permutations. Your blood type is as unique as your genes. Still, when selecting blood for patient transfusion, the current standard of care only considers eight blood types: A+/-, B+/-, AB+/-, and O+/- **.

Patients who receive multiple transfusions – such as leukemia patients, other cancers, kidney disease, bone marrow disorders, and sickle cell disease, are at risk for adverse transfusion responses. Precision Blood is the answer to better blood transfusion treatments, and San Diego Blood Bank is working to make it a reality.

We invite you to join with San Diego Blood Bank in our mission to usher in a new era of medicine through Precision Blood. With your support, we can build a future where transfusion medicine is more personalized and effective, achieving better outcomes for patients and helping them live happier, longer lives.


 
 
My sister received a blood product from San Diego Blood Bank and it was the first time I had ever heard of them. Being a Clinical Laboratory Scientist, I saw the opportunity to work here and make an impact on an issue I am passionate about, that directly affects my family.
— Josephine Ola, SDBB Quality Control Lab
JoJo_Employee.jpg
 

“Kaiser-Permanente is very pleased with San Diego Blood Bank’s Precision Blood Program and see much benefit to our patients in the expansion of Precision Blood practices. Due to this technology at San Diego Blood Bank, rapid turnaround time, and relatively low cost associated, we have implemented a policy to genotype all sickle cell disease and thalassemia children and provide them with genotype compatible blood as we believe there is tremendous return in the reduction in morbidity and mortality over the patient’s life span.”


References:

*Lögdberg, L., Reid, M. E., Lamont, R. E., & Zelinski, T. (2005). Human blood group genes 2004: chromosomal locations and cloning strategies. Transfusion medicine reviews, 19(1), 45–57, and Lögdberg, L., Reid, M. E., & Zelinski, T. (2011). Human blood group genes 2010: chromosomal locations and cloning strategies revisited. Transfusion medicine reviews, 25(1), 36–46.

**Owen R. (2000). Karl Landsteiner and the first human marker locus. Genetics, 155(3), 995–998, and Westhoff C. M. (2004). The Rh blood group system in review: a new face for the next decade. Transfusion, 44(11), 1663–1673.